Abstract: Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group, R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

Abstract: Systems, methods, and articles of manufacture for providing promotions at vending machines, such as by providing vending machine subscriptions to a category of products, are disclosed.

Abstract: Systems, methods, and articles of manufacture for providing promotions at vending machines, such as by providing vending machine subscriptions to a category of products, are disclosed.

Abstract: In accordance with one or more embodiments, a promotion redeemable at a vending machine is determined. The promotion comprises an offer distinct from a general offer to sell products from the vending machine at posted prices. The promotion is output (e.g., via an output device of a vending machine, an output device of a peripheral device of a vending machine, an output device of a customer device, or a combination thereof). In some embodiments, the promotion may be determined such that it satisfies the goal of increasing the profitability of the vending machine and/or the goal of conserving an inventory of coins in the vending machine. In some embodiments, determining a promotion may comprise constructing a promotion instance by populating a parameter of a promotion type with a value selected based on one or more rules.

Abstract: In accordance with one or more embodiments, a promotion redeemable at a vending machine is determined. The promotion comprises an offer distinct from a general offer to sell products from the vending machine at posted prices. The promotion is output (e.g., via an output device of a vending machine, an output device of a peripheral device of a vending machine, an output device of a customer device, or a combination thereof). In some embodiments, the promotion may be determined such that it satisfies the goal of increasing the profitability of the vending machine and/or the goal of conserving an inventory of coins in the vending machine. In some embodiments, determining a promotion may comprise constructing a promotion instance by populating a parameter of a promotion type with a value selected based on one or more rules.

Abstract: In accordance with one or more embodiments, a promotion redeemable at a vending machine is determined. The promotion comprises an offer distinct from a general offer to sell products from the vending machine at posted prices The promotion is output (e.g., via an output device of a vending machine, an output device of a peripheral device of a vending machine, an output device of a customer device, or a combination thereof). In some embodiments, the promotion may be determined such that it satisfies the goal of increasing the profitability of the vending machine and/or the goal of conserving an inventory of coins in the vending machine. In some embodiments, determining a promotion may comprise constructing a promotion instance by populating a parameter of a promotion type with a value selected based on one or more rules.

Abstract: Heterocyclic are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C—R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl gorup, R1, R2, R3 and R4 are as defined herein, and where X is N. R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above heterocyclic derivatives.

Abstract: Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 0 to 4; X is a bond, O, S, SO, SO2, CO, or NR7; Y is a bond, O, S, SO, SO2, CO, or NR7′ wherein at least one of X and Y is other than a bond; and R1, R2, R3, R4, R5, R6, R7 and Ra, Rb, Rc, Rd are as defined herein, and are useful as antianginal, cardioprotective agents, antiischemic agents, and agents for peripheral vascular disease including intermittent claudication. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, arrhythmia, peripheral vascular diseases (PVD), including peripheral atherosclerotic disease (PAD), including intermittent claudication, Raynaud's diseases, and LeRiches Syndrome, pain, parethesia or discomfort in the lower limb and gluteal regions produced by vascular (e.g.